Evaluation of Intra-Arterial Ad-p53 Combined With Capecitabine in Patients With Unresectable Liver Metastases of Colorectal Carcinoma and Other Solid Tumors as Well as Primary Hepatocellular Carcinoma (HCC)

Trial Profile

Evaluation of Intra-Arterial Ad-p53 Combined With Capecitabine in Patients With Unresectable Liver Metastases of Colorectal Carcinoma and Other Solid Tumors as Well as Primary Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Contusugene ladenovec (Primary)
  • Indications Colorectal cancer; Liver cancer; Liver metastases; Solid tumours
  • Focus Adverse reactions
  • Sponsors MultiVir
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results assessing ability of Ad-p53 to reverse immune checkpoint inhibitor resistance and abscopal efficacay presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 18 May 2017 According to a MultiVir media release, company plans to amend this clinical protocol to include treatment with immune checkpoint inhibitors.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top